RBC Capital Reiterates a Buy Rating on Legend Biotech Corporation (LEGN)

Group 1 - Legend Biotech Corporation (NASDAQ:LEGN) is considered a strong buy stock by Wall Street, with a Buy rating and a price target of $77.00 set by RBC Capital [1] - The company reported CARVYKTI net trade sales of approximately $439 million in fiscal Q2 2025, with positive long-term outcomes in the CARTITUDE-1 study, where one-third of patients remained progression-free for five years or more [2] - As of June 30, Legend Biotech had cash and cash equivalents, along with time deposits totaling $1.0 billion [2] Group 2 - Legend Biotech is a clinical-stage company focused on developing, discovering, manufacturing, and commercializing novel therapies for oncology and other indications [3] - The company operates advanced cell therapies across a variety of technology platforms and has a presence in the US, China, and other geographical segments [3]